Drug-Induced Acneiform Eruptions

  • Ha K. Do
  • Navid Ezra
  • Stephen E. Wolverton


Acne vulgaris is a polymorphic inflammatory skin disease, clinically characterized by mixture of comedones, superficial and deep inflamed papules, pustules, and nodules. It is a chronic inflammation of the pilosebaceous unit. Acneiform drug eruptions are a monomorphic inflammatory skin disease lacking comedones with lesions typically in the same stage. This type of drug eruption has an abrupt onset and is often associated with various medications (Table 54.1). The pathogenesis of acneiform drug eruptions is poorly understood; documented evidence when available will be presented under the specific drug categories in this chapter.


Epidermal Growth Factor Receptor Tumor Necrosis Factor Inhibitor Epidermal Growth Factor Receptor Inhibitor Gold Sodium Thiomalate Pilosebaceous Unit 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


  1. 1.
    Brunner MJ, Riddell Jr JM, Best WR. Cutaneous side effects of ACTH cortisone and pregnenolone therapy. J invest Dermatol. 1951;16:205–10.PubMedGoogle Scholar
  2. 2.
    Clementson B, Smidt AC. Periorificial dermatitis due to systemic corticosteroids in children: report of two cases. Pediatric Dermatol. 2012;29:331–2.Google Scholar
  3. 3.
    Fung MA, Berger TG. A prospective study of acute-onset steroid acne associated with administration of intravenous corticosteroids. Dermatology. 2000;200:43–4.PubMedGoogle Scholar
  4. 4.
    Plewig G, Kligman AM. Induction of acne by topical steroids. Arch Dermatol Forsch. 1973;247:29–52.PubMedGoogle Scholar
  5. 5.
    Hengge UR, Ruzicka T, Schwartz RA, Cork MJ. Adverse effects of topical glucocorticosteroids. J Am Acad Dermatol. 2006;54:1–15. quiz 6–8.PubMedGoogle Scholar
  6. 6.
    Monk B, Cunliffe WJ, Layton AM, Rhodes DJ. Acne induced by inhaled corticosteroids. Clin Exp Dermatol. 1993;18:148–50.PubMedGoogle Scholar
  7. 7.
    Hughes JR, Higgins EM, du Vivier AW. Acne associated with inhaled glucocorticosteroids. BMJ. 1992;305:1000.PubMedGoogle Scholar
  8. 8.
    Guillot B. Adverse skin reactions to inhaled corticosteroids. Exp Opin Drug Saf. 2002;1:325–9.Google Scholar
  9. 9.
    Cohen HJ. Perioral dermatitis. J Am Acad Dermatol. 1981;4:739–40.PubMedGoogle Scholar
  10. 10.
    Wells K, Brodell RT. Topical corticosteroid “addiction”. A cause of perioral dermatitis. Postgrad Med. 1993;93:225–30.PubMedGoogle Scholar
  11. 11.
    Hurwitz RM. Steroid acne. J Am Acad Dermatol. 1989;21:1179–81.PubMedGoogle Scholar
  12. 12.
    Bedane C, Souyri N. Induced acne. Ann Dermatol Venereol. 1990;117:53–8.PubMedGoogle Scholar
  13. 13.
    Gloor M, Funder H, Franke M. Effect of topical application of dexamethasone on Propionibacteria in the pilosebaceous duct. Eur J Clin Pharmacol. 1978;14:53–6.PubMedGoogle Scholar
  14. 14.
    Gloor M, Mildenberger KH. On the influence of an external therapy with dexamethasone-21-sodium-m-sulfobenzoate on the amount of free fatty acids in the skin surface lipids. Arch Dermatol Res. 1978;261:33–8.PubMedGoogle Scholar
  15. 15.
    Shibata M, Katsuyama M, Onodera T, Ehama R, Hosoi J, Tagami H. Glucocorticoids enhance Toll-like receptor 2 expression in human keratinocytes stimulated with Propionibacterium acnes or proinflammatory cytokines. J Invest Dermatol. 2009;129:375–82.PubMedGoogle Scholar
  16. 16.
    Scott III MJ, Scott AM. Effects of anabolic-androgenic steroids on the pilosebaceous unit. Cutis. 1992;50:113–6.PubMedGoogle Scholar
  17. 17.
    Scott Jr MJ, Scott 3rd MJ. Dermatologists and anabolic-androgenic drug abuse. Cutis. 1989;44:30–5.PubMedGoogle Scholar
  18. 18.
    Fyrand O, Fiskaadal HJ, Trygstad O. Acne in pubertal boys undergoing treatment with androgens. Acta Derm Venereol. 1992;72:148–9.PubMedGoogle Scholar
  19. 19.
    Heydenreich G. Testosterone and anabolic steroids and acne fulminans. Arch Dermatol. 1989;125:571–2.PubMedGoogle Scholar
  20. 20.
    Melnik B, Jansen T, Grabbe S. Abuse of anabolic-androgenic steroids and bodybuilding acne: an underestimated health problem. J Dtsch Dermatol Ges. 2007;5:110–7.PubMedGoogle Scholar
  21. 21.
    Gerber PA, Kukova G, Meller S, Neumann NJ, Homey B. The dire consequences of doping. Lancet. 2008;372:656.PubMedGoogle Scholar
  22. 22.
    Greenberg RD. Acne vulgaris associated with antigonadotropic (Danazol) therapy. Cutis. 1979;24:431–3.PubMedGoogle Scholar
  23. 23.
    Ilse JR, Greenberg HL, Bennett DD. Levonorgestrel-releasing intrauterine system and new-onset acne. Cutis. 2008;82:158.PubMedGoogle Scholar
  24. 24.
    Olsson SE, Odlind V, Johansson E. Androgen levels in women using Norplant implants. Contraception. 1986;34:157–67.PubMedGoogle Scholar
  25. 25.
    Grupper C. New iatrogenic acne: acne caused by amineptin (Survector). Ann Dermatol Venereol. 1988;115:1174–6.PubMedGoogle Scholar
  26. 26.
    Thioly-Bensoussan D, Charpentier A, Triller R, et al. Iatrogenic acne caused by amineptin (Survector). Apropos of 8 cases. Ann Dermatol Venereol. 1988;115:1177–80.PubMedGoogle Scholar
  27. 27.
    Vexiau P, Gourmel B, Husson C, et al. Severe lesions of acne type induced by chronic amineptin poisoning: apropos of 6 cases. Ann Dermatol Venereol. 1988;115:1180–2.PubMedGoogle Scholar
  28. 28.
    Ponte CD. Maprotiline-induced acne. Am J Psychiatry. 1982;139:141.PubMedGoogle Scholar
  29. 29.
    Kusumi Y. A cutaneous side effect of lithium: report of two cases. Dis Nerv Syst. 1971;32:853–4.PubMedGoogle Scholar
  30. 30.
    Ruiz-Maldonado R, Perez de Francisco C, Tamayo L. Lithium dermatitis. JAMA. 1973;224:1534.PubMedGoogle Scholar
  31. 31.
    Yoder FW. Letter: acneiform eruption due to lithium carbonate. Arch Dermatol. 1975;111:396–7.PubMedGoogle Scholar
  32. 32.
    Rifkin A, Kurtin SB, Quitkin F, Klein DF. Lithium-induced folliculitis. Am J Psychiatry. 1973;130:1018–9.PubMedGoogle Scholar
  33. 33.
    Heng MC. Lithium carbonate toxicity. Acneiform eruption and other manifestation. Arch Dermatol. 1982;118:246–8.PubMedGoogle Scholar
  34. 34.
    Heng MC. Cutaneous manifestations of lithium toxicity. Br J Dermatol. 1982;106:107–9.PubMedGoogle Scholar
  35. 35.
    Hesse S, Berbis P, Lafforgue P, Acquaviva PC, Pastor MJ, Privat Y. Acne and enthesiopathy during anti-epileptic treatment. Ann Dermatol Venereol. 1992;119:655–8.PubMedGoogle Scholar
  36. 36.
    Jenkins RB, Ratner AC. Diphenylhydantoin and acne. New Engl J Med. 1972;287:148.PubMedGoogle Scholar
  37. 37.
    Nielsen JN, Licht RW, Fogh K. Two cases of acneiform eruption associated with lamotrigine. J Clin Psychiatry. 2004;65:1720–2.PubMedGoogle Scholar
  38. 38.
    Joffe H, Cohen LS, Suppes T, et al. Valproate is associated with new-onset oligoamenorrhea with hyperandrogenism in women with bipolar disorder. Biol Psychiatry. 2006;59:1078–86.PubMedGoogle Scholar
  39. 39.
    Stankler L, Campbell AG. Neonatal acne vulgaris: a possible feature of the fetal hydantoin syndrome. Br J Dermatol. 1980;103:453–5.PubMedGoogle Scholar
  40. 40.
    Norris JF, Cunliffe WJ. Phenytoin-induced gum hypertrophy improved by isotretinoin. Int J Dermatol. 1987;26:602–3.PubMedGoogle Scholar
  41. 41.
    Mishra B, Praharaj SK, Prakash R, Sinha VK. Aripiprazole-induced acneiform eruption. Gen Hosp Psychiatry. 2008;30:479–81.PubMedGoogle Scholar
  42. 42.
    Warthan MM, Jumper CA, Smith JL. Acneiform eruption induced by Iressa (gefitinib) tablets used to treat non-small cell lung cancer. J Drugs Dermatol. 2004;3:569–70.PubMedGoogle Scholar
  43. 43.
    Schalock PC, Zug KA. Acneiform reaction to erlotinib. Dermatitis. 2007;18:230–1.PubMedGoogle Scholar
  44. 44.
    Kardaun SH, van Duinen KF. Erlotinib-induced florid acneiform rash complicated by extensive impetiginization. Clin Exp Dermatol. 2008;33:46–9.PubMedGoogle Scholar
  45. 45.
    Martin JM, Jorda E, Monteagudo C, Alonso V, Garcia L, Villalon G. Follicular acneiform eruption induced by imatinib. J Eur Acad Dermatol Venereol. 2006;20:1368–70.PubMedGoogle Scholar
  46. 46.
    Lee JE, Lee SJ, Lee HJ, Lee JH, Lee KH. Severe acneiform eruption induced by cetuximab (Erbitux). Yonsei Med J. 2008;49:851–2.PubMedGoogle Scholar
  47. 47.
    Molinari E, De Quatrebarbes J, Andre T, Aractingi S. Cetuximab-induced acne. Dermatology. 2005;211:330–3.PubMedGoogle Scholar
  48. 48.
    Rowinsky EK, Schwartz GH, Gollob JA, et al. Safety, pharmacokinetics, and activity of ABX-EGF, a fully human anti-epidermal growth factor receptor monoclonal antibody in patients with metastatic renal cell cancer. J Clin Oncol. 2004;22:3003–15.PubMedGoogle Scholar
  49. 49.
    Sun G, Wasko CA, Hsu S. Acneiform eruption following anti-TNF-alpha treatment: a report of three cases. J Drugs Dermatol. 2008;7:69–71.PubMedGoogle Scholar
  50. 50.
    Jacot W, Bessis D, Jorda E, et al. Acneiform eruption induced by epidermal growth factor receptor inhibitors in patients with solid tumours. Br J Dermatol. 2004;151:238–41.PubMedGoogle Scholar
  51. 51.
    DeWitt CA, Siroy AE, Stone SP. Acneiform eruptions associated with epidermal growth factor receptor-targeted chemotherapy. J Am Acad Dermatol. 2007;56:500–5.PubMedGoogle Scholar
  52. 52.
    Eames T, Landthaler M, Karrer S. Severe acneiform skin reaction during therapy with erlotinib (Tarceva), an epidermal growth factor receptor (EGFR) inhibitor. Eur J Dermatol. 2007;17:552–3.PubMedGoogle Scholar
  53. 53.
    Journagan S, Obadiah J. An acneiform eruption due to erlotinib: prognostic implications and management. J Am Acad Dermatol. 2006;54:358–60.PubMedGoogle Scholar
  54. 54.
    Perez-Soler R, Saltz L. Cutaneous adverse effects with HER1/EGFR-targeted agents: is there a silver lining? J Clin Oncol. 2005;23:5235–46.PubMedGoogle Scholar
  55. 55.
    Segaert S, Van Cutsem E. Clinical signs, pathophysiology and management of skin toxicity during therapy with epidermal growth factor receptor inhibitors. Ann Oncol. 2005;16:1425–33.PubMedGoogle Scholar
  56. 56.
    Sladden MJ, Clarke PJ, Mitchell B. Infliximab-induced acne: report of a third case. Br J Dermatol. 2008;158:172.PubMedGoogle Scholar
  57. 57.
    Michot C, Guillot B, Dereure O. Lenalidomide-induced acute acneiform folliculitis of the head and neck: not only the anti-EGF receptor agents. Dermatology. 2010;220:49–50.PubMedGoogle Scholar
  58. 58.
    Lee PK, Dover JS. Recurrent exacerbation of acne by granulocyte colony-stimulating factor administration. J Am Acad Dermatol. 1996;34:855–6.PubMedGoogle Scholar
  59. 59.
    Petukhova TA, Novoa RA, Honda K, Koon HB, Gerstenblith MR. Acneiform eruptions associated with vemurafenib. J Am Acad Dermatol. 2013;68:e97–9.PubMedGoogle Scholar
  60. 60.
    Lowe L, Herbert AA. Cystic and comedonal acne: a side effect of etretinate therapy. Int J Dermatol. 1989;28:482.PubMedGoogle Scholar
  61. 61.
    Menter A, Boyd A. Cystic acne in psoriatic patients undergoing etretinate therapy. J Am Acad Dermatol. 1988;18:751–2.PubMedGoogle Scholar
  62. 62.
    Bajwa ZH, Sami N, Flory C. Severe acne as a side effect of propranolol and nadolol in a migraineur. Headache. 1999;39:758–60.PubMedGoogle Scholar
  63. 63.
    Burkhart CG. Quinidine-induced acne. Arch Dermatol. 1981;117:603–4.PubMedGoogle Scholar
  64. 64.
    Fidan K, Kandur Y, Sozen H, Gonul II, Dalgic A, Soylemezoglu O. How often do we face side effects of sirolimus in pediatric renal transplantation? Transplant Proc. 2013;45:185–9.PubMedGoogle Scholar
  65. 65.
    Kunzle N, Venetz JP, Pascual M, Panizzon RG, Laffitte E. Sirolimus-induced acneiform eruption. Dermatology. 2005;211:366–9.PubMedGoogle Scholar
  66. 66.
    Lubbe J, Sorg O, Male PJ, Saurat JH, Masouye I. Sirolimus-induced inflammatory papules with acquired reactive perforating collagenosis. Dermatology. 2008;216:239–42.PubMedGoogle Scholar
  67. 67.
    Momin SB, Peterson A, Del Rosso JQ. A status report on drug-associated acne and acneiform eruptions. J Drugs Dermatol. 2010;9:627–36.PubMedGoogle Scholar
  68. 68.
    Mahe E, Morelon E, Lechaton S, et al. Acne in recipients of renal transplantation treated with sirolimus: clinical, microbiologic, histologic, therapeutic, and pathogenic aspects. J Am Acad Dermatol. 2006;55:139–42.PubMedGoogle Scholar
  69. 69.
    Mahe E, Morelon E, Lechaton S, et al. Cutaneous adverse events in renal transplant recipients receiving sirolimus-based therapy. Transplantation. 2005;79:476–82.PubMedGoogle Scholar
  70. 70.
    Bakos L, Bakos RM. Focal acne during topical tacrolimus therapy for vitiligo. Arch Dermatol. 2007;143:1223–4.PubMedGoogle Scholar
  71. 71.
    Antille C, Saurat JH, Lubbe J. Induction of rosaceiform dermatitis during treatment of facial inflammatory dermatoses with tacrolimus ointment. Arch Dermatol. 2004;140:457–60.PubMedGoogle Scholar
  72. 72.
    El Sayed F, Ammoury A, Dhaybi R, Bazex J. Rosaceiform eruption to pimecrolimus. J Am Acad Dermatol. 2006;54:548–50.PubMedGoogle Scholar
  73. 73.
    el-Shahawy MA, Gadallah MF, Massry SG. Acne: a potential side effect of cyclosporine A therapy. Nephron. 1996;72:679–82.PubMedGoogle Scholar
  74. 74.
    Azurdia RM, Graham RM, Weismann K, Guerin DM, Parslew R. Acne keloidalis in caucasian patients on cyclosporin following organ transplantation. Br J Dermatol. 2000;143:465–7.PubMedGoogle Scholar
  75. 75.
    Bencini PL, Crosti C, Sala F, et al. Gingival hyperplasia by nifedipine. Report of a case. Acta Derm Venereol. 1985;65:362–5.PubMedGoogle Scholar
  76. 76.
    Formicone F, Fargnoli MC, Pisani F, Rascente M, Famulari A, Peris K. Cutaneous manifestations in Italian kidney transplant recipients. Transplant Proc. 2005;37:2527–8.PubMedGoogle Scholar
  77. 77.
    Schmoeckel C, von Liebe V. Acneiform exanthema caused by azathioprine. Hautarzt. 1983;34:413–5.PubMedGoogle Scholar
  78. 78.
    Hjortshoj A. Lichen planus and acne provoked by gold. Acta Derm Venereol. 1977;57:165–7.PubMedGoogle Scholar
  79. 79.
    Blatt J, Lee PA. Severe acne and hyperandrogenemia following dactinomycin. Med Pediatr Oncol. 1993;21:373–4.PubMedGoogle Scholar
  80. 80.
    Bereston ES. Reactions to antituberculous drugs. J Invest Dermatol. 1959;33:427–39.PubMedGoogle Scholar
  81. 81.
    Cohen LK, George W, Smith R. Isoniazid-induced acne and pellagra. Occurrence in slow inactivators of isoniazid. Arch Dermatol. 1974;109:377–81.PubMedGoogle Scholar
  82. 82.
    Amann W. Can acneiform skin lesions caused by Inh-medication Be considered as being within the concept of acne vulgaris? Dermatol Wochenschr. 1964;150:647–51.PubMedGoogle Scholar
  83. 83.
    Holdiness M. Adverse cutaneous reactions to antituberculosis drugs. Int J Dermatol. 1985;24:280–5.PubMedGoogle Scholar
  84. 84.
    De D, Dogra S, Kaur I. Dapsone induced acute photosensitivity dermatitis; a case report and review of literature. Lepr Rev. 2007;78:401–4.PubMedGoogle Scholar
  85. 85.
    Ismail R. Acne fulminans with dapsone induced haemolysis: a case report. Med J Malaysia. 1987;42:124–6.PubMedGoogle Scholar
  86. 86.
    Pelclova D, Urban P, Preiss J, et al. Adverse health effects in humans exposed to 2,3,7,8-tetrachlorodibenzo-p-dioxin (TCDD). Rev Environ Health. 2006;21:119–38.PubMedGoogle Scholar
  87. 87.
    Tindall JP. Chloracne and chloracnegens. J Am Acad Dermatol. 1985;13:539–58.PubMedGoogle Scholar
  88. 88.
    Plewig G, Jansen T. Acneiform dermatoses. Dermatology. 1998;196:102–7.PubMedGoogle Scholar
  89. 89.
    Webster GF. Pustular drug reactions. Clin Dermatol. 1993;11:541–3.PubMedGoogle Scholar
  90. 90.
    Fisher AA. Drug eruptions in geriatric patients. Cutis. 1976;18:402–9.PubMedGoogle Scholar
  91. 91.
    Sherertz EF. Acneiform eruption due to "megadose" vitamins B6 and B12. Cutis. 1991;48:119–20.PubMedGoogle Scholar
  92. 92.
    Braun-Falco O, Lincke H. The problem of vitamin B6/B12 acne. A contribution on acne medicamentosa (author's transl). MMW Munch Med Wochenschr. 1976;118:155–60.PubMedGoogle Scholar
  93. 93.
    Frankel EB. Acne secondary to white petrolatum use. Arch Dermatol. 1985;121:589–90.PubMedGoogle Scholar
  94. 94.
    O'Brien TJ. Acneiform eruption associated with the use of a cow udder ointment. Australas J Dermatol. 1990;31:119.PubMedGoogle Scholar
  95. 95.
    Barefoot S. Acneiform eruption produced by use of tetraethylthiuramdisulfide. JAMA. 1951;147:1653.Google Scholar
  96. 96.
    Pembroke AC, Saxena SR, Kataria M, Zilkha KD. Acne induced by dantrolene. Br J Dermatol. 1981;104:465–8.PubMedGoogle Scholar
  97. 97.
    Joynt RL. Dantrolene sodium: long-term effects in patients with muscle spasticity. Arch Phys Med Rehabil. 1976;57:212–7.PubMedGoogle Scholar
  98. 98.
    Jones C, Bleehen SS. Acne induced by PUVA treatment. Br Med J. 1977;2:866.PubMedGoogle Scholar
  99. 99.
    Nielsen EB, Thormann J. Acne-like eruptions induced by PUVA-treatment. Acta Derm Venereol. 1978;58:374–5.PubMedGoogle Scholar
  100. 100.
    Humbert P. Induced acne. Rev Prat. 2002;52:838–40.PubMedGoogle Scholar
  101. 101.
    Frumess GM, Lewis HM. Light-sensitive seborrheid. AMA Arch Derm. 1957;75:245–8.PubMedGoogle Scholar
  102. 102.
    Hjorth N, Sjolin KE, Sylvest B, Thomsen K. Acne aestivalis–Mallorca acne. Acta Derm Venereol. 1972;52:61–3.PubMedGoogle Scholar

Copyright information

© Springer Science+Business Media New York 2014

Authors and Affiliations

  1. 1.Department of DermatologyIndiana University School of MedicineNew YorkUSA

Personalised recommendations